Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY19 is not expected to be complete until June, 2020.

  1. Topic 375: 18F PET Tracer For Imaging PD-L1 (Moonshot)

    SBC: SIBTECH, INC.            Topic: NCI

    New therapies, designed to enhance anti-tumor immunity are based on the blockade of the checkpoint components, either PD-1 on immune cells or PD-L1 on tumor cells. This strategy, while being spectacularly successful in some patients for some cancers, fails for many other patients. The expression of PD-L1 is highly dynamic and its prevalence within tumors can vary significantly over time. The curre ...

    SBIR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  2. Development of Novel RAD-Hard ASICs and a Modular Design Methodology Using Asynchronous Architectures

    SBC: Nanomatronix, LLC            Topic: MDA18007

    The NMT/UA team propose to develop a radiation-hardened, low power, and highly robust delay-insensitive asynchronous circuit design methodology in 90nm technology, prototyped by designing a SET/SEL/SEU immune asynchronous microcontroller test chip (PIC 16C57, for example).The proposed Phase 1 SBIR effort will focus on design, simulation, prototyping and demonstration of the key functional blocks o ...

    SBIR Phase I 2018 Department of DefenseMissile Defense Agency
  3. Nucleobase aminosugars with reduced ototoxicity

    SBC: NUBAD, LLC            Topic: Y

    PROJECT SUMMARYAminoglycosides are one of the cheapest and well known antibiotics in clinical use for overyearsbut one of the major limitations in their use is their ototoxicityWe are developing fast and low cost methods to develop aminoglycosides with antiribosomal activities and reduced toxicityIn this projectwe will identify novel aminoglycoside antibacterialsthat show reduced ototoxicityComple ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  4. Multicolor Photoacoustic Malaria Detector

    SBC: CytoAstra, LLC            Topic: NIAID

    Summary Malaria continues to be a global health prioritywith almost half of the world s populationbillionat risk and arounddeaths each yearOvertreatment is caused by lack of diagnosis and contributes to resistancea huge threat as illustrated by artemisinin resistance in Southeast AsiaLittle progress has been made in the novel methods to diagnose malarialet alone in reliably identifying asymptomati ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  5. Therapeutic Inhibition of MIF to Improve Glucocorticoid Response

    SBC: L2 DIAGNOSTICS, LLC            Topic: NIAID

    Abstract Despite the advent of biological therapiesglucocorticoidsGCsremain the most widely prescribed medicines for the management of inflammatory diseases such as lupusasthmamultiple sclerosisand rheumatoid arthritisHoweverlong term and high dose GC use is inevitably accompanied by systemic toxicityThere are no adjunctive therapies that could enhance the disease modifying effects of GCs at low d ...

    SBIR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  6. Development of an Autism Spectrum Disorder Screening Test based upon Metabolic Profiling of Fresh Blood Samples

    SBC: CIRCA BIOSCIENCE, LLC            Topic: 102

    Autism spectrum disorderASDis a neurodevelopmental disorder characterized by significant deficits in reciprocal social interactionsimpaired communication and restrictedrepetitive behaviorswith a prevalence ofinchildren in the USEarly intervention programs have been shown to be effective for improving IQlanguageand social skills for toddlers as young asmonths of ageDiagnosis of ASD is currently bas ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  7. A Method to Increase Buprenorphine Treatment Capacity and Effectiveness

    SBC: CBT4CBT, LLC            Topic: R42

    The goal of this fast track STTR proposal is to expand buprenorphine maintenance therapy for opioiddependent patientsOvermillion people in the US are addicted to opiatesProviding effective agonist therapymethadone or buprenorphinecoupled with behavioral counseling greatly improves outcomesreduces morbidityand reduces societal costsMethadone maintenance treatment has been limited due to complex sta ...

    STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  8. Proteasome inhibitor re-sensitizing molecules for treatment of refractory multiple myeloma

    SBC: Leukogene Therapeutics Inc.            Topic: 102

    Project Summary Abstract Multiple MyelomaMMis the second most common form of blood cancer and remains an incurable and deadly diseaseProteasome inhibitorPItherapy is a cornerstone in the treatment of MMbut resistance to this class of agent is an emerging challenge in the clinicNew therapeutic approaches that specifically target resistance are needed to maximize responses and ultimately produce cur ...

    STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  9. Development of a hybrid transcatheter mitral valve replacement and repair device

    SBC: Dura LLC            Topic: NHLBI

    PROJECT SUMMARYMitral regurgitationMRis the most prevalent valvular heart disease in the U Saffecting approximatelyof the populationThere aremillion patients in the US with moderate to severe MR requiring treatmentHoweveronly approximatelypatients in the U Sundergo surgery for MR each year due to concerns about procedural complexity and patient safetyThere is great enthusiasm among the heart valve ...

    SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  10. Development of TP-317 for the Induction and Maintenance of Remission in Ulcerative Colitis Patients

    SBC: Thetis Pharmaceuticals LLC            Topic: 300

    ABSTRACTThetis plans to investigate TPan innovative and potential first in class therapeutic agentas an oral therapy for the induction and maintenance of remission of intestinal inflammation symptoms in ulcerative colitisUCpatientsWhile the precise etiology of UC is unknownit is thought to result from an inappropriate inflammatory response to commensal gut bacteria in genetically susceptible indiv ...

    SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government